Group 1 - The article discusses the resurgence of SPACs (Special Purpose Acquisition Companies) in 2025 after a decline in popularity due to disappointing returns and increased federal oversight [4][5] - New SPAC issuances more than doubled from 2024 to 2025, indicating a positive trend in the market, driven by experienced SPAC sponsors returning [5] - Cormorant Asset Management has launched Helix Acquisition Corp. III, raising $150 million through an IPO, with plans to focus on healthcare or healthcare-related industries [8] Group 2 - Helix Acquisition Corp. III sold 15 million shares at $10 each, exceeding its initial projection by 2.5 million shares, and began trading on Nasdaq under the ticker "HLXC" [8] - Cormorant Asset Management manages over $2.4 billion and has previously taken three SPACs public since 2022, successfully finding merger partners for its earlier SPACs [8] - The current market environment presents unique opportunities for SPACs, as many drug startups have remained private longer, creating a backlog of mature companies ready for public markets [7][8]
Biotech investor Cormorant secures $150M for another SPAC deal